{"id":515010,"date":"2021-07-20T08:18:13","date_gmt":"2021-07-20T12:18:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/"},"modified":"2021-07-20T08:18:13","modified_gmt":"2021-07-20T12:18:13","slug":"relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/","title":{"rendered":"Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">July 20, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Relmada\u00a0Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),\u00a0today announced the acquisition of development and commercial rights to a novel psilocybin and derivate program from Arbormentis LLC in all ex-<span class=\"xn-location\">Asia<\/span> territories, including the U.S. and Europe.\u00a0 Relmada will collaborate with Arbormentis on the development of new therapies targeting neurological and psychiatric disorders, leveraging its understanding of neuroplasticity, and focusing on this emerging new class of drugs targeting the neuroplastogen mechanism of action. \u00a0Importantly, neuroplasticity plays a key role in the activity of REL-1017, Relmada&#8217; s lead program, which is currently in Phase III for the treatment of depression. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg\" title=\"Relmada Therapeutics Corporate Logo (PRNewsFoto\/Relmada Therapeutics, Inc.)\" alt=\"Relmada Therapeutics Corporate Logo (PRNewsFoto\/Relmada Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Under the terms of the agreement, Relmada will pay Arbormentis LLC an upfront fee of <span class=\"xn-money\">$15 million<\/span>, consisting of a mix of cash and equity, in addition to potential milestone payments totaling in excess of <span class=\"xn-money\">$150 million<\/span>, related to pre-specified development and commercialization milestones.\u00a0 Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement. <\/p>\n<p>The development of REL-1017 is progressing as planned, and we continue to expect top-line data from the human abuse potential study assessing REL-1017 as compared to oxycodone in <span class=\"xn-chron\">July 2021<\/span>.<\/p>\n<p>Arbormentis LLC is a privately-held drug discovery company engaged in potentially transformative innovations for CNS diseases. The new licensed program stems from an international collaboration among distinguished U.S., European and Swiss scientists that has focused on the discovery and development of compounds that promote neural plasticity. \u00a0Dr. <span class=\"xn-person\">Paolo Manfredi<\/span>, Relmada&#8217; s co-founder and Chief Scientific Officer and co-inventor of REL-1017, and Dr. <span class=\"xn-person\">Marco Pappagallo<\/span>, Relmada&#8217; s Chief Medical Officer, are among the scientists of Arbormentis.<\/p>\n<p>&#8220;Today&#8217;s agreement furthers our commitment to identifying and advancing groundbreaking treatments to address diseases of the CNS. \u00a0This transaction expands Relmada&#8217; s R&amp;D pipeline and leverages our core expertise in neural plasticity.\u00a0 Additionally, this novel psylocibin program represents a strong strategic fit with REL-1017, our lead compound currently in Phase III for the treatment of major depressive disorder (MDD),&#8221; said <span class=\"xn-person\">Sergio Traversa<\/span>, CEO of Relmada Therapeutics, Inc.<\/p>\n<p>Dr Manfredi added, &#8220;My Arbormentis colleagues and I are excited and proud to bring this novel psilocybin platform into Relmada.\u00a0 We are thrilled to move forward with Relmada based on our confidence in the company&#8217;s demonstrated clinical progress with REL-1017 and significant expertise in neural plasticity. This pipeline addition positions Relmada at the forefront of development of new therapies with neuroplastogen potential.&#8221;<\/p>\n<p>\n        <b>About\u00a0Relmada\u00a0Therapeutics, Inc.\u00a0<\/b>\n      <\/p>\n<p>Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada&#8217; s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. Learn more at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3233598-1&amp;h=884568838&amp;u=http%3A%2F%2Fwww.relmada.com%2F&amp;a=www.relmada.com\" rel=\"nofollow noopener\">www.relmada.com<\/a>.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;will,&#8221; &#8220;will likely result,&#8221; &#8220;will continue,&#8221; &#8220;plans to,&#8221; &#8220;potential,&#8221; &#8220;promising,&#8221; and similar expressions. These statements are based on management&#8217;s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading &#8220;Risk Factors&#8221; set forth in the Company&#8217;s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.<\/p>\n<p>\n        <b>Investor Contact: <br \/><\/b><br \/>\n        <span class=\"xn-person\">Tim McCarthy<\/span><br \/>\n        <br \/>LifeSci Advisors <br \/>212-915-2564 <br \/><a target=\"_blank\" href=\"mailto:Tim@LifeSciAdvisors.com\" rel=\"nofollow noopener\">Tim@LifeSciAdvisors.com<\/a><\/p>\n<p>\n        <b>Media Inquiries: <br \/><\/b>FischTank PR<br \/><a target=\"_blank\" href=\"mailto:Relmada@FischTankPR.com\" rel=\"nofollow noopener\">Relmada@FischTankPR.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH48890&amp;sd=2021-07-20\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc-301337402.html\">https:\/\/www.prnewswire.com\/news-releases\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc-301337402.html<\/a><\/p>\n<p>SOURCE  Relmada Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH48890&amp;Transmission_Id=202107200815PR_NEWS_USPR_____PH48890&amp;DateId=20210720\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK, July 20, 2021 \/PRNewswire\/ &#8212;\u00a0Relmada\u00a0Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),\u00a0today announced the acquisition of development and commercial rights to a novel psilocybin and derivate program from Arbormentis LLC in all ex-Asia territories, including the U.S. and Europe.\u00a0 Relmada will collaborate with Arbormentis on the development of new therapies targeting neurological and psychiatric disorders, leveraging its understanding of neuroplasticity, and focusing on this emerging new class of drugs targeting the neuroplastogen mechanism of action. \u00a0Importantly, neuroplasticity plays a key role in the activity of REL-1017, Relmada&#8217; s lead program, which is currently in Phase III for the treatment of depression. Under the terms of the agreement, Relmada &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-515010","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, July 20, 2021 \/PRNewswire\/ &#8212;\u00a0Relmada\u00a0Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),\u00a0today announced the acquisition of development and commercial rights to a novel psilocybin and derivate program from Arbormentis LLC in all ex-Asia territories, including the U.S. and Europe.\u00a0 Relmada will collaborate with Arbormentis on the development of new therapies targeting neurological and psychiatric disorders, leveraging its understanding of neuroplasticity, and focusing on this emerging new class of drugs targeting the neuroplastogen mechanism of action. \u00a0Importantly, neuroplasticity plays a key role in the activity of REL-1017, Relmada&#8217; s lead program, which is currently in Phase III for the treatment of depression. Under the terms of the agreement, Relmada &hellip; Continue reading &quot;Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-20T12:18:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC\",\"datePublished\":\"2021-07-20T12:18:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/\"},\"wordCount\":796,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/168770\\\/relmada_logo_hd_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/\",\"name\":\"Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/168770\\\/relmada_logo_hd_logo.jpg\",\"datePublished\":\"2021-07-20T12:18:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/168770\\\/relmada_logo_hd_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/168770\\\/relmada_logo_hd_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/","og_locale":"en_US","og_type":"article","og_title":"Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC - Market Newsdesk","og_description":"PR Newswire NEW YORK, July 20, 2021 \/PRNewswire\/ &#8212;\u00a0Relmada\u00a0Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),\u00a0today announced the acquisition of development and commercial rights to a novel psilocybin and derivate program from Arbormentis LLC in all ex-Asia territories, including the U.S. and Europe.\u00a0 Relmada will collaborate with Arbormentis on the development of new therapies targeting neurological and psychiatric disorders, leveraging its understanding of neuroplasticity, and focusing on this emerging new class of drugs targeting the neuroplastogen mechanism of action. \u00a0Importantly, neuroplasticity plays a key role in the activity of REL-1017, Relmada&#8217; s lead program, which is currently in Phase III for the treatment of depression. Under the terms of the agreement, Relmada &hellip; Continue reading \"Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-20T12:18:13+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC","datePublished":"2021-07-20T12:18:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/"},"wordCount":796,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/","name":"Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg","datePublished":"2021-07-20T12:18:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-the-acquisition-of-development-and-commercial-rights-to-novel-psilocybin-and-derivates-program-from-arbormentis-llc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/515010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=515010"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/515010\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=515010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=515010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=515010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}